A single-arm, phase II trial assessing the combination of AK105 and anlotinib in first-line treatment for persistent, recurrent, or metastatic cervical cancer

被引：0
|
作者：
Guo, Ruixia [1 ]
Qiu, Haifeng [1 ]
Wang, Qian [1 ]
Su, Ke [1 ]
Chang, Lei [1 ]
Cai, Mingbo [1 ]
Mao, Meng [1 ]
Bian, Aiping [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5530
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Penpulimab plus anlotinib plus chemo-less therapy in first-line treatment for persistent, recurrent, or metastatic cervical cancer: A single-arm, phase II study (ALTN-AK105-II-06)
    Xu, Q.
    Liu, J.
    Li, L.
    Lin, Y.
    Chen, Y.
    Song, Y.
    Luo, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S520 - S520
  • [2] Anlotinib plus penpulimab plus chemo-less therapy in first-line treatment for persistent, recurrent, or metastatic cervical cancer: A single-arm, phase II study (ALTN-AK105-II-06)
    Xu, Qin
    Liu, Jing
    Li, Li
    Lin, Yibin
    Chen, Ying
    Luo, Lan
    Zhu, Mingxuan
    Zhang, Huiqi
    Zhu, Fei
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S279 - S280
  • [3] Penpulimab plus platinum-based chemotherapy combined with anlotinib in first-line treatment for persistent, recurrent, or metastatic cervical cancer: A single-arm, openlabel phase. study (ALTN-AK105-II-06)
    Xu, Qin
    Liu, Jing
    Chen, Ying
    Song, Yanwen
    Luo, Lan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Efficacy and safety of Anlotinib in combination with gemcitabine and cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A single-arm clinical trial
    Xiao, Zhehao
    Chen, Weiling
    Du, Youqin
    Zeng, Fanyan
    Su, Fang
    Huang, Shiting
    Qu, Song
    INTERNATIONAL JOURNAL OF CANCER, 2025,
  • [5] Tislelizumab in combination with anlotinib as first-line treatment for unresectable hepatocellular carcinoma: A single-arm, phase II clinical trial.
    Laoguo, Shi-xue
    Huang, Huasheng
    Zeng, Jie
    Jiang, Yangfeng
    Liu, Cuizhen
    Mo, Ning
    Zhu, GuangZhi
    Ma, Fuchao
    Peng, Tao
    Zeng, Zhiming
    Ma, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 576 - 576
  • [6] A prospective, single-arm, open-label, phase II clinical trial on efficacy and safety of cadonilimab plus anlotinib for recurrent, metastatic or persistent cervical cancer
    Yang, Chunxu
    Sun, Shaoxing
    Xiang, Qingming
    Chen, Min
    Mei, Zijie
    Wu, Qiuji
    Qiu, Hui
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S290 - S290
  • [7] First-Line Treatment of Locally Advanced or Metastatic Pulmonary Lymphoepitheliomalikecarcinoma: A Multicenter, Single-Arm, Phase II Trial
    Zhou, C.
    Lin, X.
    Li, S.
    Sun, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S96 - S97
  • [8] BEVACIZUMAB COMBINED WITH FIRST-LINE CARBOPLATIN AND PACLITAXEL FOR METASTATIC/RECURRENT/PERSISTENT CERVICAL CANCER: PRIMARY RESULTS FROM THE GLOBAL SINGLE-ARM PHASE II CECILIA STUDY
    Colombo, N.
    Dreosti, L.
    McCormack, M.
    Nogueira-Rodrigues, A.
    Scambia, G.
    Roszak, A.
    Donica, M.
    Ulker, B.
    Gonzalez-Martin, A.
    Redondo, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A22 - A23
  • [9] A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer
    Jagiello-Gruszfeld, Agnieszka
    Tjulandin, Sergei
    Dobrovolskaya, Natalya
    Manikhas, Alexey
    Pienkowski, Tadeusz
    DeSilvio, Michelle
    Ridderheim, Mona
    Abbey, Rowena
    ONCOLOGY, 2010, 79 (1-2) : 129 - 135
  • [10] Toripalimab combined with bevacizumab and chemotherapy as first-line treatment for refractory, recurrent or metastatic cervical cancer: a single-arm, open-label, phase II TRIA
    Li, Chen
    Peng, Peng
    Yao, Hairong
    Liu, Dantong
    He, Yonglan
    Liu, Shikai
    Cheng, Ninghai
    Cao, Dongyan
    Xiang, Yang
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A38 - A38
12345